Premium
P1‐312: Improved efficacy of mesenchymal stem cells by co‐administration with galantamine in a tau hyperphophorylated model of Alzheimer's disease in rats
Author(s) -
Misra Shubham,
Chopra Kanwaljit,
Saikia Uma Nahar,
Medhi Bikash
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.527
Subject(s) - galantamine , oxidative stress , mesenchymal stem cell , medicine , morris water navigation task , neuroinflammation , pharmacology , endocrinology , inflammation , disease , donepezil , pathology , dementia , hippocampus
SUVN-502 on acetylcholinesterase inhibitors (donepezil, 1 mg/kg, s.c. or rivastigmine, 0.5 mg/kg, s.c.) evoked acetylcholine modulation was evaluated in the hippocampus of freely moving male Wistar rats. Results: SUVN-502 (3 mg/kg, p.o.) alone produced moderate increase in acetylcholine levels. However, in combination with donepezil (1 mg/kg, s.c.), SUVN-502 produced significant increase in hippocampal acetylcholine levels compared to donepezil. Similarly, acetylcholine increase produced by the combination of SUVN-502 (3 mg/kg, p.o.) and rivastigmine (0.5 mg/kg, s.c.) was significantly higher than that of rivastigmine. SUVN-502 produced synergistic effects in combination with cholinesterase inhibitors in object recognition task. Conclusions: SUVN-502 potentiates the effects of acetylcholinesterase inhibitors i.e., donepezil and rivastigmine in animalmodels of cognition and neurochemistry. These results indicate that similar potentiation could contribute to the procognitive effects in acetylcholinesterase-treated Alzheimer’s disease patients. Thus, the combination of SUVN-502 with acetylcholinesterase inhibitor may be beneficial in the treatment of cognitive deficits associated with Alzheimer’s disease.